| Catalog No. | DF909018 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 0.156 μg/ml |
|---|
| Range | 0.31-5 μg/mL |
|---|
| Accession | P01138 |
|---|
| Applications | ELISA |
|---|
| Detection method | Colorimetric |
|---|
| Assay type | Quantitative |
|---|
| Recovery | 80-120% |
|---|
| Shipping | 2-8 ℃ |
|---|
| Stability and Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
|---|
| Specifications | Tanezumab |
|---|
| Alternate Names | PF-04383119, RN624, CAS: 880266-57-9 |
|---|
| Background | Tanezumab (RN624) is a recombinant humanized anti- nerve growth factor (NGF) monoclonal antibody (IgG2 type) that works by inhibiting the binding of NGF to its receptors. It was developed by Pfizer as a treatment for pain. |
|---|
| Note | For Research Use Only. |
|---|
